Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Duration: November 1, 2007
to
March 31, 2009
General Issues: Health Issues , Medicare/Medicaid , Pharmacy
Spending: about $150,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: House of Representatives, U.S. Senate,, U.S. Senate, Congressional Budget Office (CBO), Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2009
Jennings Policy Strategies terminated an engagement in which they represented GENERAL MOTORS CORP on May 11, 2009.
Original Filing: 300168956.xml
Lobbying Issues
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Type of Issue
Health Issues Medicare/Medicaid Pharmacy
1st Quarter, 2009
In Q1, Jennings Policy Strategies lobbied for GENERAL MOTORS CORP , earning $30,000. The report was filed on April 20, 2009.
Original Filing: 300165562.xml
Lobbying Issues
Advocated for cost containment policies including generic access, health information technology, and comparative effectiveness research (including but not limited to H.R. 1427, S. 726, H.R. 1548, and H.R. 1) and policies that promote competition in the pharmaceutical marketplace.
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Type of Issue
Health Issues Medicare/Medicaid Pharmacy
4th Quarter, 2008
In Q4, Jennings Policy Strategies lobbied for GENERAL MOTORS CORP , earning $30,000. The report was filed on Jan. 21, 2009.
Original Filing: 300134155.xml
Lobbying Issues
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Congressional Budget Office (CBO)
Type of Issue
Health Issues Medicare/Medicaid Pharmacy
3rd Quarter, 2008
In Q3, Jennings Policy Strategies lobbied for GENERAL MOTORS CORP , earning $30,000. The report was filed on Oct. 20, 2008.
Original Filing: 300104639.xml
Lobbying Issues
-Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness.-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including
but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Congressional Budget Office (CBO)
Lobbying Issues
-Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness.-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (includingbut not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Congressional Budget Office (CBO)
Lobbying Issues
-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Agencies Lobbied
U.S. House of Representatives U.S. Senate Congressional Budget Office (CBO)
2nd Quarter, 2008
In Q2, Jennings Policy Strategies lobbied for GENERAL MOTORS CORP , earning $30,000. The report was filed on July 21, 2008.
Original Filing: 300077102.xml
Lobbying Issues
-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace
-Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Congressional Budget Office (CBO)
Type of Issue
Health Issues Medicare/Medicaid Pharmacy
1st Quarter, 2008
In Q1, Jennings Policy Strategies lobbied for GENERAL MOTORS CORP , earning $30,000. The report was filed on April 17, 2008.
Original Filing: 300041321.xml
Lobbying Issues
-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace
-Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness and policies related to Medicare coverage of end-stage renal disease services
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Health Issues Medicare/Medicaid Pharmacy
0th Quarter, 2007
In MM, Jennings Policy Strategies lobbied for GENERAL MOTORS CORP , earning $80,000. The report was filed on Aug. 6, 2007.
Original Filing: 200046228.xml
Lobbying Issues
-Advocate for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace
-Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness
Lobbying Issues
-Advocated for cost containment policies including generic access and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace
-Advocated for policies promoting broad health coverage reform, including support for initiatives designed to reform retiree health liabilities that undermine competitiveness
Type of Issue
Pharmacy Medicare/Medicaid
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate